Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) EBITDA (2016 - 2025)

Altimmune (ALT) has disclosed EBITDA for 16 consecutive years, with -$19.0 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA rose 15.59% to -$19.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$84.1 million, a 18.55% increase, with the full-year FY2024 number at -$95.0 million, down 7.71% from a year prior.
  • EBITDA was -$19.0 million for Q3 2025 at Altimmune, up from -$22.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$14.9 million in Q1 2021 to a low of -$33.5 million in Q3 2021.
  • A 5-year average of -$22.4 million and a median of -$22.2 million in 2025 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: tumbled 279.24% in 2021, then rose 29.4% in 2022.
  • Altimmune's EBITDA stood at -$23.9 million in 2021, then increased by 9.65% to -$21.6 million in 2022, then plummeted by 46.04% to -$31.5 million in 2023, then rose by 26.06% to -$23.3 million in 2024, then increased by 18.52% to -$19.0 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's EBITDA are -$19.0 million (Q3 2025), -$22.2 million (Q2 2025), and -$19.6 million (Q1 2025).